STOCK TITAN

Boundless Bio, Inc. - BOLD STOCK NEWS

Welcome to our dedicated news page for Boundless Bio (Ticker: BOLD), a resource for investors and traders seeking the latest updates and insights on Boundless Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Boundless Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Boundless Bio's position in the market.

Rhea-AI Summary
Boundless Bio (Nasdaq: BOLD) initiates first-in-human Phase 1/2 trial for BBI-825, a novel ribonucleotide reductase inhibitor, targeting oncogene amplified cancers. The study aims to address resistance gene amplifications in locally advanced or metastatic cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
-
Rhea-AI Summary
Boundless Bio (Nasdaq: BOLD) presents promising preclinical and clinical data on BBI-355, a novel CHK1 inhibitor, at AACR Annual Meeting 2024. The findings highlight BBI-355's efficacy in overcoming ecDNA-mediated resistance to targeted therapies, showing antitumor activity and potential in combating chemotherapy resistance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.75%
Tags
none
-
Rhea-AI Summary
Boundless Bio, Inc. (Nasdaq: BOLD) announces pricing of its IPO, offering 6,250,000 shares at $16.00 per share, expecting gross proceeds of $100.0 million. The company's common stock will trade under the ticker symbol 'BOLD' on Nasdaq. The offering is set to close on April 2, 2024, with underwriters having an option to purchase additional shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Boundless Bio, Inc.

Nasdaq:BOLD

BOLD Rankings

BOLD Stock Data

234.85M
791.75k
11.47%
48.85%
Biotechnology
Healthcare
Link
United States
San Diego